Immunovia AB (publ)
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jeff Borcherding
- Full Time Employees
- 9
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- Medicon Village Lund Sweden 223 63
- IPO Date
- Jun 28, 2019
- Website
- immunovia.com
- Similar Companies
- Business
- Immunovia AB (publ) (IMMNOV; IMMVF) is a Sweden-based diagnostic company that develops and commercializes blood tests for the early detection of pancreatic cancer and autoimmune diseases using its proprietary IMMray platform, which employs antibody biomarker microarray analysis, machine learning, and bioinformatics to identify disease-specific biomarker signatures. The company offers core products including PancreaSure, a highly accurate blood test for detecting pancreatic cancer at stages 1 or 2 in high-risk individuals; IMMray PanCan-d, a laboratory-developed test (LDT) for early pancreatic cancer detection commercialized in the United States since 2021 through its U.S. subsidiary Immunovia Inc.; and IMMray SLE-d for differential diagnosis of lupus, alongside laboratory testing services from accredited reference labs in the USA and Sweden. Founded in 2007 and headquartered in Lund, Sweden, Immunovia operates primarily in the United States as its first commercial market, with clinical labs and significant staff based there, targeting high-risk pancreatic cancer patients such as those with familial or genetic predispositions. Recent developments include the September 2025 U.S. launch of PancreaSure, adopted by 10 leading pancreatic cancer centers; a strategic shift to commercialization highlighted in Q3 2025 earnings with reduced operating losses and a SEK 100 million rights issue to fund launch and reimbursement efforts; pursuit of Medicare reimbursement by 2026 at an established rate of $897 per test; and ongoing NIH-funded clinical utility studies, bridge financing, and plans for commercial partnerships to support volume growth into 2027.
Immunovia AB (publ) (IMMVF) Q1 2026 Earnings Call Transcript
Immunovia AB (publ) (IMMVF) Q4 2025 Earnings Call Transcript
Immunovia AB (publ) (IMMVF) Q3 2025 Earnings Call Transcript
Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test
Immunovia to host a webcast to share more data from the successful VERIFI clinical validation study
Immunovia announces another successful clinical validation of its next-generation pancreatic cancer test
Immunovia AB (Publ) presents Nomination Committee
Immunovia CEO and board members announce intention to fully exercise their TO2 warrants
Immunovia presents data from model development study at meeting of the PRECEDE pancreatic cancer research consortium
Immunovia presents data from model development study at 2024 AACR Advances in Pancreatic Cancer medical conference
Immunovia announces updated financial calendar
Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection
Immunovia to present at Gilmartin Group's Emerging Growth Company Showcase